

Docket No. SCH 1655

IN RE APPLICATION OF: Klaus STÖCKEMANN et al.

SERIAL NO: 09/117,357

FILED: September 22, 1998

FOR: PHARMACEUTICAL COMBINED PREPARATION AND ITS USE IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS



1654

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED
FEB 17 2000
TC 1600 MAIL ROOM

SIR:

Transmitted herewith is an amendment in the above-identified application.

- ☐ No additional fee is required
- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been established by a verified statement previously submitted.
- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been established by a verified statement submitted herewith.
- ☐ Additional documents filed herewith:

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	30	MINUS	30	0	× \$18 =	\$0.00
INDEPENDENT	5	MINUS	5	0	× \$78 =	\$0.00
		<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			+ \$260 =	\$0.00
		TOTAL OF ABOVE CALCULATIONS				\$0.00
		<input type="checkbox"/> Reduction by 50% for filing by Small Entity				\$0.00
		<input type="checkbox"/> Recordation of Assignment			+ \$40 =	\$0.00
		TOTAL				\$0.00

- A check in the amount of \$0.00 is attached.
- Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.
- If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Brion P. Heaney, Esq.
Registration No. 32,542

2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201
Tel. (703) 243-6333
Fax (703) 243-6410

BPH:imm\K:\PAT\Sch\1655\Amend Transm 2-14-2000.wpd

RECEIVED
FEB 16 2000
TC 1700 MAIL ROOM


IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In re Application of:

Klaus STOCKMANN et al.

Serial No.: 09/117,357

Filed: September 22, 1998



Art Unit: 1654

Examiner: C. Delacroix-Muirheid

Title: PHARMACEUTICAL COMBINED PREPARATION AND ITS USE IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS

SUPPLEMENTAL AMENDMENT

Sir:

In response to the Office Action of January 19, 2000, please amend the above-identified application as follows:

IN THE CLAIMS:

Please **cancel claims 1-9**.

Please **add claims 10-39** as follows:

10. A pharmaceutical composition comprising one or more LHRH analogues and an anti-estrogen having tissue-selective estrogenic activity.

11. A ^{method} ~~composition~~ according to claim ³⁴ 10, wherein said LHRH analogue is an LHRH agonist.

12. A ^{method} ~~composition~~ according to claim ³⁴ 10, wherein said LHRH analogue is Leuprorelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂, Ramorelix, or Zoladex.

13. A ^{method} ~~composition~~ according to claim ³⁴ 10, wherein said one or more LHRH analogues is orally bioavailable.

RECEIVED
FEB 17 2000
TC 1600 MAIL ROOM

RECEIVED
FEB 16 2000
TC 700 MAIL ROOM